Cargando…

Polo-Like Kinase 2: From Principle to Practice

Polo-like kinase (PLK) 2 is an evolutionarily conserved serine/threonine kinase that shares the n-terminal kinase catalytic domain and the C-terminal Polo Box Domain (PBD) with other members of the PLKs family. In the last two decades, mounting studies have focused on this and tried to clarify its r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chuanyong, Ni, Chuangye, Lu, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309260/
https://www.ncbi.nlm.nih.gov/pubmed/35898867
http://dx.doi.org/10.3389/fonc.2022.956225
_version_ 1784753118732353536
author Zhang, Chuanyong
Ni, Chuangye
Lu, Hao
author_facet Zhang, Chuanyong
Ni, Chuangye
Lu, Hao
author_sort Zhang, Chuanyong
collection PubMed
description Polo-like kinase (PLK) 2 is an evolutionarily conserved serine/threonine kinase that shares the n-terminal kinase catalytic domain and the C-terminal Polo Box Domain (PBD) with other members of the PLKs family. In the last two decades, mounting studies have focused on this and tried to clarify its role in many aspects. PLK2 is essential for mitotic centriole replication and meiotic chromatin pairing, synapsis, and crossing-over in the cell cycle; Loss of PLK2 function results in cell cycle disorders and developmental retardation. PLK2 is also involved in regulating cell differentiation and maintaining neural homeostasis. In the process of various stimuli-induced stress, including oxidative and endoplasmic reticulum, PLK2 may promote survival or apoptosis depending on the intensity of stimulation and the degree of cell damage. However, the role of PLK2 in immunity to viral infection has been studied far less than that of other family members. Because PLK2 is extensively and deeply involved in normal physiological functions and pathophysiological mechanisms of cells, its role in diseases is increasingly being paid attention to. The effect of PLK2 in inhibiting hematological tumors and fibrotic diseases, as well as participating in neurodegenerative diseases, has been gradually recognized. However, the research results in solid organ tumors show contradictory results. In addition, preliminary studies using PLK2 as a disease predictor and therapeutic target have yielded some exciting and promising results. More research will help people better understand PLK2 from principle to practice.
format Online
Article
Text
id pubmed-9309260
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93092602022-07-26 Polo-Like Kinase 2: From Principle to Practice Zhang, Chuanyong Ni, Chuangye Lu, Hao Front Oncol Oncology Polo-like kinase (PLK) 2 is an evolutionarily conserved serine/threonine kinase that shares the n-terminal kinase catalytic domain and the C-terminal Polo Box Domain (PBD) with other members of the PLKs family. In the last two decades, mounting studies have focused on this and tried to clarify its role in many aspects. PLK2 is essential for mitotic centriole replication and meiotic chromatin pairing, synapsis, and crossing-over in the cell cycle; Loss of PLK2 function results in cell cycle disorders and developmental retardation. PLK2 is also involved in regulating cell differentiation and maintaining neural homeostasis. In the process of various stimuli-induced stress, including oxidative and endoplasmic reticulum, PLK2 may promote survival or apoptosis depending on the intensity of stimulation and the degree of cell damage. However, the role of PLK2 in immunity to viral infection has been studied far less than that of other family members. Because PLK2 is extensively and deeply involved in normal physiological functions and pathophysiological mechanisms of cells, its role in diseases is increasingly being paid attention to. The effect of PLK2 in inhibiting hematological tumors and fibrotic diseases, as well as participating in neurodegenerative diseases, has been gradually recognized. However, the research results in solid organ tumors show contradictory results. In addition, preliminary studies using PLK2 as a disease predictor and therapeutic target have yielded some exciting and promising results. More research will help people better understand PLK2 from principle to practice. Frontiers Media S.A. 2022-07-08 /pmc/articles/PMC9309260/ /pubmed/35898867 http://dx.doi.org/10.3389/fonc.2022.956225 Text en Copyright © 2022 Zhang, Ni and Lu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhang, Chuanyong
Ni, Chuangye
Lu, Hao
Polo-Like Kinase 2: From Principle to Practice
title Polo-Like Kinase 2: From Principle to Practice
title_full Polo-Like Kinase 2: From Principle to Practice
title_fullStr Polo-Like Kinase 2: From Principle to Practice
title_full_unstemmed Polo-Like Kinase 2: From Principle to Practice
title_short Polo-Like Kinase 2: From Principle to Practice
title_sort polo-like kinase 2: from principle to practice
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309260/
https://www.ncbi.nlm.nih.gov/pubmed/35898867
http://dx.doi.org/10.3389/fonc.2022.956225
work_keys_str_mv AT zhangchuanyong pololikekinase2fromprincipletopractice
AT nichuangye pololikekinase2fromprincipletopractice
AT luhao pololikekinase2fromprincipletopractice